RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signallingJIm,
I would say all this work on the tumor environment and the sequential administration of pela before other agents is all nearly unknown territory, barely explored. But the article that came out last summer about the effects on the TME is extremely powerful and in one of the world's top science journals.
Other biotechs addressing cancer would be rocketing on such news. Because we are ONCY with a price below $2 US and a long history of waiting, with no other drugs or sources of revenure, our price has not been affected much.
But in the end, a buyout will have an undeniable, irrefutable effect on the share price, despite the slow volume and lack of substantial institutional interest at present.